The Ebola virus break out in Western Africa controlled a lot of the stories in 2014. The highly contagious pathogen spreads rapidly and kills over half of those who become infected, resulting in serious panics across multiple continents. While most of the dead are in Africa, health workers did bring the pathogen home to other countries and continents.
For all of the bad news and focus on doomsday eventualities on what the virus could do, there are essentially dome economic benefits of Ebola virus flare-ups. The economic benefits principally breakdown between nonprofit or state groups and for-profit biotechnology firms.
Central authority or aid associations like the Red Cross or the CDC have a tendency to see increases in funding in events such as these. The industrial advantages to them are direct and help out those on the ground suffering or aiding and containing an outbreak.
This containment keeps commercial interruption when funding is satisfactory to turn the tide of an onset.
The longer term business benefits of Ebola virus outbreaks are biotech firms working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, which has been given blessings by the FDA to broaden testing on in its experimental Ebola drug for larger scale medical tests.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications prove to be of price.
While the 2014 Ebola break out is the first to have caught global attention as much as it did, it was barely the first onset. Others have happened, and more will happen in times to come. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see an increase in business in the future.
For all of the bad news and focus on doomsday eventualities on what the virus could do, there are essentially dome economic benefits of Ebola virus flare-ups. The economic benefits principally breakdown between nonprofit or state groups and for-profit biotechnology firms.
Central authority or aid associations like the Red Cross or the CDC have a tendency to see increases in funding in events such as these. The industrial advantages to them are direct and help out those on the ground suffering or aiding and containing an outbreak.
This containment keeps commercial interruption when funding is satisfactory to turn the tide of an onset.
The longer term business benefits of Ebola virus outbreaks are biotech firms working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, which has been given blessings by the FDA to broaden testing on in its experimental Ebola drug for larger scale medical tests.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications prove to be of price.
While the 2014 Ebola break out is the first to have caught global attention as much as it did, it was barely the first onset. Others have happened, and more will happen in times to come. Any business which has an Ebola drug or vaccine on the market that proves effective can be certain to see an increase in business in the future.
About the Author:
my name is alfred obi I've been a biological scientist for years teaching individuals on ebola virus disease update and ebola virus disease which has influenced most states in africa be at liberty to visit my website for your free protecting gear on ebola thanks.